Compare TG Therapeutics Inc (TGTX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.98, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators show neutral conditions. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds despite recent dividend distributions.

The ETF faces significant interest rate risk as the Federal Reserve maintains higher rates, though current yields offer attractive income potential. Key risks include further rate hikes and inflation persistence, while potential catalysts include economic slowdowns that could drive bond prices higher. Institutional flows show mixed sentiment with recent large inflows despite price declines.